中国人群总胆固醇水平与脑卒中及其亚型关系的前瞻性研究暨脂联素与心血管疾病的meta分析
|
摘要
背景与目的：
脑卒中是当今世界危害人类健康最重要的疾病之一,具有极高的致残率和较高的致死率。与国外研究相比,中国人群总胆固醇(TC)水平与脑卒中及其亚型,如出血性脑卒中的发病和死亡风险之间关系的大规模队列研究较少且结果不明确。本研究以中国队列研究协作组(China Cohort Studies Collaboration, CCSC)以及十一五代谢综合征队列人群为研究对象,从多个角度探讨基线TC水平与脑卒中及其亚型之间的关系,为更好地预防和控制我国脑卒中的发病和死亡提供一定的科学依据。
资料与方法：
本研究中CCSC队列纳入分析者62,603人,十一五队列纳入分析者19,796人,共82,399人,其中男性47,875人,女性34,524人。两队列人群根据基线TC水平按照成人血脂异常防治指南(以下简称指南)划分标准分为四组,比较各组间基线特征的差别。采用COX比例风险回归模型,以TC<5.18mmol/L (200mg/dl)为对照组,计算其余各水平组(20mg/dl为步长)脑卒中、缺血性脑卒中、出血性脑卒中发病和死亡的风险比(Hazard Ratio, HR)及相应的95%置信区间(95%CI)。同时计算TC水平每升高1mmol/L相应的结局事件发生的HR(95%CI)。计算人群归因危险度百分比(PARP),分析脑卒中及其亚型归因于高TC血症的比例。
结果：
CCSC.总随访人年为573,894.92,最终发生脑卒中1,068例(缺血性脑卒中367例、出血性脑卒中361例和未分类脑卒中340例)。十一五队列总随访人年为156,306.26,最终发生脑卒中400例(缺血性脑卒中227例、出血性脑卒中148例和未分类脑卒中25例)。
年龄标化后,十一五队列的基线TC平均水平比CCSC增加0.23mmol/L(8.88mg/d1)。脑卒中、缺血性脑卒中以及出血性脑卒中的标化发病率,无论在男性和女性人群中,十一五队列都高于CCSC。在男性人群中,脑卒中、缺血性脑卒中以及出血性脑卒中的标化死亡率均为十一五队列高于CCSC。在女性人群中脑卒中以及出血性脑卒中的标化死亡率为CCSC高于十一五队列,而缺血性脑卒中的标化死亡率在两个队列中基本一致。
CCSC中,按照指南分为四组,与对照组相比,多因素调整后,TC在5.18-5.68mmol/L(200-219mg/d1)以及>6.22mmol/L(240mg/d1)组缺血性脑卒中的发病风险分别增加55%和77%,致死性缺血性脑卒中的发生风险分别增加99%和131%(均P<0.05)。TC水平每升高1mmol/L,缺血性脑卒中和致死性缺血性脑卒中的发病风险分别增加21%和25%(均P<0.05)。十一五队列中,按照指南分为四组,与对照组相比,多因素调整后,TC在各水平组发生脑卒中、缺血性脑卒中和出血性脑卒中风险的HR值均没有统计学意义(均P>0.05)。
两个队列合并的分析结果显示,按照指南分为四组,与对照组相比,多因素调整后,TC在各水平组缺血性脑卒中的发病风险分别增加31%、45%和61%(均P<0.05)；TC在5.18-5.68mmol/L(200-219mg/d1)和≥6.22mmol/L(240mg/d1)组发生致死性缺血性脑卒中的风险分别增加80%和131%(均P<0.05)。多因素调整后,TC水平每升高1mmol/L,脑卒中的发病风险增加5%,缺血性脑卒中的发病风险增加20%,致死性缺血性脑卒中的发生风险增加24%,均P<0.05。PARP分析结果显示,脑卒中的发病3.6%可归因于TC水平升高,缺血性脑卒中的发病11.1%可归因于TC水平升高。亚组分析结果显示,多因素调整后,TC水平每升高1mmol/L,缺血性脑卒中的发病风险在男性和女性人群中分别增加20%和17%；在年龄<60岁和≥60岁人群中分别增加18%和19%；在SBP<140mmHg和≥140mmHg人群中分别增加14%和25%；在吸烟和不吸烟人群中分别增加17%和21%(均P<0.05)。与对照组相比,多因素调整后,在男性、年龄<60岁、SBP≥140mmHg和吸烟人群中,TC在5.69-6.21(220-239)和≥6.22mmol/L(240mg/d1)组缺血性脑卒中的发病风险均显著增加；在SBP≥140mmHg人群中,TC≥6.22mmol/L(240mg/d1)组脑卒中的发病风险增加32%(P=0.01)；在吸烟人群中,TC≥6.22mmol/L(240mg/d1)组脑卒中和出血性脑卒中的发病风险分别增加33%(P=0.02)和50%(P=0.04)。此外,合并其他危险因素时,随着危险因素数目的增加,脑卒中及其亚型的发病风险均增加。在相同危险因素条件下,与TC<5.18mmol/L(200mg/d1)者相比,TC≥5.18mmol/L(200mg/d1)的个体脑卒中及其亚型的发病风险均增加。
结论：
近二三十年来,中国人群TC水平呈现升高的趋势。脑卒中、缺血性脑卒中和出血性脑卒中的发病率也不断增加。随着TC水平的增加,脑卒中和缺血性脑卒中的发病风险均不断增加,致死性缺血性脑卒中的风险也显著增加。吸烟人群中,与TC<5.18mmol/L(200mg/d1)组相比,TC>6.22mmol/L(240mg/d1)组出血性脑卒中的发病风险显著增加。合并其他危险因素时,在相同危险因素条件下,高TC水平者脑卒中、缺血性脑卒中和出血性脑卒中的发病风险均增加。鉴于我国人群TC水平和脑卒中发病率不断升高,及TC水平对脑卒中及其亚型发病的危险性,通过平衡膳食,提倡健康生活方式,减少血脂紊乱和降低人群血清TC水平,是减少与控制我国人群脑卒中发病率和危害的重要公共卫生策略和措施之一。
背景与目的：
既往研究发现脂联素可以调节糖代谢以及脂质代谢,并具有抗炎以及抗动脉粥样硬化的作用。这些结果提示脂联素可能具有降低冠心病发病风险的作用。此外,许多研究探讨了脂联素基因(ADIPOQ)单核苷酸多态性,即+45T>G(rs2241766),+276G>T(rs1501299)以及-11377C>G(rs266729),与心血管疾病风险的关系,然而这些研究并没有得到一致的结果。本研究拟通过meta分析评价ADIPOQ三个多态位点与心血管疾病风险的相关性,并且通过对脂联素水平与冠心病发病关系的前瞻性研究资料进行meta分析,以评估脂联素水平对冠心病发病风险的影响。资料与方法：
两名评价者独立系统检索Pubmed、EMbase、CBM、维普、万方等数据库,获取ADIPOQ三个多态位点与心血管疾病风险的关联研究文献,以及脂联素水平与冠心病关系的前瞻性研究文献。在2012年2月之前发表的研究被纳入进行meta分析。本研究中,ADIPOQ与心血管疾病的meta分析主要考虑病例对照组之间等位基因频率比较的比值比(Odds Ratio,OR值)；脂联素与冠心病的1neta分析主要提取各研究的多因素调整的相对风险度(RR)及95%置信区间(95%CI)等数据。采用Q检验及I2统计量评估研究间的异质性,根据异质性选择固定效应或随机效应模型合并RR值或OR值及95%CI；使用Egger线性回归检验估计发表偏倚。本研究使用相关评分标准对所有纳入的研究进行评分。
结果：
ADIPOQ三个多态位点与心血管疾病风险的meta分析纳入37个病例对照研究,包含6,398个病例和10,829个对照(rs2241766)；8,392个病例和18,730个对照(rs1501299)；以及7,835个病例和14,023个对照(rs266729)。三个多态位点都与心血管疾病存在显著关联。合并OR值分别为：rs2241766,1.22(95%CI：1.07,1.39；P=0.004)；rs1501299,0.90(95%CI：0.83,0.97；P=0.007)；rs266729,1.09(95%CI：1.01,1.17；P=0.032)。rs2241766和rs1501299与冠心病也显著相关,合并OR值分别为1.29(95%CI：1.09,1.52；P=0.004)和0.89(95%CI：0.81,0.99；P=0.025)。rs2241766和rs266729与脑卒中存在显著关联。固定效应模型合并OR值分别为1.28(95%CI：1.12,1.46；P<0.0001)和1.20(95%CI：1.08,1.34；P=0.0001)。三个位点与高血压之间关联都没有统计学显著性。分析发现纳入的研究间存在显著异质性。对rs266729与CVD之间的关系按照种族进行亚组分析可以消除异质性,欧洲和亚洲人群亚组分析的I2分别为26.1%和O。亚组分析发现只有在亚洲人群中的相关性是显著的,合并OR值(固定效应模型)为1.29(95%CI：1.18,1.42；P<0.001)；在欧洲人群中相关性并不显著,合并OR值(固定效应模型)为1.01(95%CI：0.94,1.08；P=0.880)。分析中发现rs2241766与CVD关系的研究存在发表偏倚(Egger's检验,P=0.007)。
脂联素水平与冠心病meta分析共纳入12个前瞻性研究,其中包括8个巢式病例对照研究和4个队列研究。最终共有11,461名研究对象纳入分析,其中4,132名研究对象发生冠心病。结果显示脂联素水平与冠心病的发病风险呈负相关。合并的RR值为0.83(95%CI：0.69,0.98；P=0.031)。亚组分析结果显示在男性、女性以及年龄小于65岁的群体中都存在这种负相关性。本项研究中没有发现发表偏倚(P=0.911)。
结论：
本项meta分析显示ADIPOQ基因单核苷酸多态性与心血管疾病之间存在显著的相关性。脂联素水平对冠心病的发生具有保护作用。我们仍然需要高质量的大规模研究来证实这些相关性。
Background and Objective:
Stroke is the most common cause of death and severe disability in the world. The relationships between serum total cholesterol (TC) level and risk of stroke and its subtypes are not well established in Asia. We used individual data from the cohorts of China Cohort Studies Collaboration (CCSC) and the Incidence and Comprehensive Control of Metabolic Syndrome Study (ICMS) to explore the impact of baseline TC level on the risks of total stroke, ischaemic and haemorrhagic stroke and its implication in the population prevention of stroke in China.
Materials and Methods:
A total of62,603participants from CCSC were included, of which data on cholesterol levels at baseline and the outcome of stroke at follow-up were all available. For ICMS, of27,020participants aged35to74at baseline,21,556participants have completed the follow-up survey and19,796participants with full information were analyzed in this study. Participants in these two cohorts were divided into four groups according to the baseline TC level, that was TC<5.18mmol/L (200mg/dl),5.18-5.67mmol/L (200-219mg/dl),5.68-6.21mmol/L (220-239mg/dl) and>6.22mmol/L (240mg/dl). The differences of mean levels of baseline risk factors were compared. Cox regression models were used to estimate the hazard ratios (HR) and95%confidence intervals (CI) for the incidence and death of stroke and stroke subtypes. Population attributable risk percentage (PARP) was also calculated.
Results:
Over the course of573,894.92person-years of follow-up in CCSC, a total of1,068incident strokes were collected, including367ischaemic strokes,361haemorrhagic strokes and340unclassified strokes. For ICMS, after156,306.26person-years of follow-up, a total of400incident strokes were collected, including227ischaemic strokes,148haemorrhagic strokes and25unclassified strokes.
The age-adjusted mean level of baseline TC in ICMS participants was0.23mmol/L (8.88mg/dl) higher than that of CCSC participants. The age-standardized person-year incidence of stroke, ischaemic and haemorrhagic stroke were all higher for both men and women in ICMS. In male subgroup analysis, the standardized person-year mortality of stroke, ischaemic stroke and haemorrhagic stroke were all higher in men from ICMS compared with that in men from CCSC. However, the age-standardized person-year mortality of stroke and haemorrhagic stroke were higher in CCSC in women. The age-standardized person-year mortality of ischaemic stroke was basically the same in both CCSC and ICMS in women.
In CCSC, the multivariate-adjusted HRs (95%CIs) for total (fatal or nonfatal) ischemic stroke were1.55(1.17,2.06) and1.77(1.27,2.45) in TC5.18-5.68mmol/L (200-219mg/dl) and TC>6.22mmol/L (240mg/dl) groups compared with the lowest baseline TC level group, respectively. Accordingly, compared with the lowest baseline TC level group, the multivariate-adjusted HRs (95%CIs) for fatal ischemic stroke were1.99(1.22,3.24) and2.31(1.31,4.08) in TC5.18-5.68mmol/L (200-219mg/dl) and TC>6.22mmol/L (240mg/dl) groups, respectively. Each1-mmol/L increase in TC was associated with a21%greater risk of total ischemic stroke (P<0.0001). In ICMS cohort, the multivariate-adjusted HRs for stroke, ischaemic and haemorrhagic stroke were not statistically significant in TC5.18-5.68mmol/L (200-219mg/dl),5.69-6.21mmol/L (220-239mg/dl) and TC>6.22mmol/L (240mg/dl) groups compared with the lowest TC group.
For the combined data of CCSC and ICMS, the multivariate-adjusted HRs (95%CIs) for total ischemic stroke were1.31(1.04,1.65),1.45(1.10,1.91) and1.61(1.24,2.08) in TC5.18-5.68mmol/L (200-219mg/dl),5.69-6.21mmol/L (220-239mg/dl) and TC>6.22mmol/L (240mg/dl) groups compared with the lowest TC group, separately. The multivariate-adjusted HRs (95%CIs) for fatal ischemic stroke were correspondingly1.80(1.16,2.79) and2.31(1.42,3.75) in TC5.18-5.68(200-219) and TC≥6.22mmol/L (240mg/dl) groups. Each1-mmol/L increase in TC was significantly associated with a5%,20%and24%higher risk of total stroke, total ischemic stroke and fatal ischemic stroke, respectively. PARP for total stroke and total ischemic stroke was3.6%and11.1%, respectively.
The results of subgroup analyses showed that each1-mmol/L increase in TC was significantly associated with a20%higher risk of ischemic stroke for men and17%for women,18%for age<60and19%for age>60,14%for SBP<140mmHg and25%for SBP≥140mmHg, and17%for smokers and21%for never smokers. The multivariate adjusted risk of ischemic stroke was significantly increased in TC5.69-6.21(220-239) and≥6.22mmol/L (240mg/dl) for men, age<60, SBP≥140mmHg and smoker subgroups compared with the reference group. The multivariate-adjusted HR (95%CI) for stroke was1.32(1.06,1.65) in TC>6.22mmol/L (240mg/dl) group for SBP>140mmHg subgroup accordingly. In smokers, the multivariate-adjusted HRs (95%CIs) for total stroke and total haemorrhagic stroke were1.33(1.05,1.69) and1.50(1.01,2.22), respectively. Besides, an elevated HR of total stroke and its subtypes were found when considering TC with the increased number of other risk factors.
Conclusions:
In the three decades, the serum TC level in Chinese populations significantly increased, so as the incidence of stroke, ischaemic and haemorrhagic stroke in China. The baseline TC level was strongly associated with the risks of stroke and ischaemic stroke in our study. For smokers, the risk of total stroke and total haemorrhagic stroke significantly increased in TC>6.22mmol/L (240mg/dl) compared with TC<5.18mmol/L (200mg/dl). Higher TC levels were strongly associated with increased risks of stroke, ischaemic and haemorrhagic stroke.Reducing serum TC level in residents through primary prevention and lifestyle modification will have an important impact on population prevention and control of stroke in China.
Background and Objective:
Adiponectin is the most abundant circulating protein secreted by adipocytes. Previous studies have examined the associations between polymorphisms of adiponectin gene (ADIPOQ) and cardiovascular disease (CVD), but those studies have been inconclusive. There is also uncertainty about the association between concentrations of circulating adiponectin and coronary heart disease (CHD) risk. The aims of this study were to evaluate the relationship between three single nucleotide polymorphisms (SNPs),+45T>G (rs2241766),+276G>T (rs1501299) and-11377C Materials and Methods:
A comprehensive search was conducted to identify all studies on the association of ADIPOQ gene polymorphisms with CVD risk and the association of adiponectin levels with incident risk of CHD. The fixed and random effect pooled measures (i.e. odds ratio (OR) and95%confidence interval (CI)) were calculated in the meta-analysis. Heterogeneity among studies was evaluated using Q test and the I2. Publication bias was estimated using modified Egger's linear regression test.
Results:
Thirty-seven studies concerning the associations between the three polymorphisms of ADIPOQ gene and CVD risk were enrolled in this meta-analysis, including6,398cases and10,829controls for rs2241766,8,392cases and18,730controls for rs1501299and7,835cases and14,023controls for rs266729. The three SNPs were significantly associated with CVD, yielding pooled ORs of1.22(95%CI:1.07,1.39; P=0.004),0.90(95%CI:0.83,0.97; P=0.007) and1.09(95%CI:1.01,1.17; P=0.032) for rs2241766, rs1501299and rs266729, respectively. Rs2241766and rs1501299were significantly associated with coronary heart disease (CHD), yielding pooled ORs of1.29(95%CI:1.09,1.52; P=0.004) and0.89(95%CI:0.81,0.99; P=0.025), respectively. The pooled OR for rs266729and CHD was1.09(95%CI:0.99,1.19; P=0.090). Rs2241766and rs266729were significantly associated with stroke, yielding pooled ORs (fixed-effects method) of1.28(95%CI:1.12,1.46; P<0.0001) and1.20(95%CI:1.08,1.34; P=0.0001), respectively. The associations between the three SNPs and hypertension were not significant. Significant between-study heterogeneity and evidence of publication bias were observed in the meta-analysis.
Twelve prospective studies comprising8nested case-control studies and4cohort studies were included in the meta-analysis. A total of14,960participants were enrolled and4,132incident CHD events were observed. The pooled RR of CHD was0.83(95%CI:0.69,0.98; P=0.031). The inverse association was consistently observed in men and women and in the studies with mean age<65year. No publication bias was found in our study (P=0.911).
Conclusions:
The present meta-analysis showed that the associations between rs2241766, rs1501299and rs266729in the ADIPOQ and CVD were significant. Higher levels of adiponectin were associated with a low risk of CHD. The protective effect was consistent in men and women and in the middle-aged populations. High quality studies are still needed to confirm the associations.
脑卒中是当今世界危害人类健康最重要的疾病之一,具有极高的致残率和较高的致死率。与国外研究相比,中国人群总胆固醇(TC)水平与脑卒中及其亚型,如出血性脑卒中的发病和死亡风险之间关系的大规模队列研究较少且结果不明确。本研究以中国队列研究协作组(China Cohort Studies Collaboration, CCSC)以及十一五代谢综合征队列人群为研究对象,从多个角度探讨基线TC水平与脑卒中及其亚型之间的关系,为更好地预防和控制我国脑卒中的发病和死亡提供一定的科学依据。
资料与方法：
本研究中CCSC队列纳入分析者62,603人,十一五队列纳入分析者19,796人,共82,399人,其中男性47,875人,女性34,524人。两队列人群根据基线TC水平按照成人血脂异常防治指南(以下简称指南)划分标准分为四组,比较各组间基线特征的差别。采用COX比例风险回归模型,以TC<5.18mmol/L (200mg/dl)为对照组,计算其余各水平组(20mg/dl为步长)脑卒中、缺血性脑卒中、出血性脑卒中发病和死亡的风险比(Hazard Ratio, HR)及相应的95%置信区间(95%CI)。同时计算TC水平每升高1mmol/L相应的结局事件发生的HR(95%CI)。计算人群归因危险度百分比(PARP),分析脑卒中及其亚型归因于高TC血症的比例。
结果：
CCSC.总随访人年为573,894.92,最终发生脑卒中1,068例(缺血性脑卒中367例、出血性脑卒中361例和未分类脑卒中340例)。十一五队列总随访人年为156,306.26,最终发生脑卒中400例(缺血性脑卒中227例、出血性脑卒中148例和未分类脑卒中25例)。
年龄标化后,十一五队列的基线TC平均水平比CCSC增加0.23mmol/L(8.88mg/d1)。脑卒中、缺血性脑卒中以及出血性脑卒中的标化发病率,无论在男性和女性人群中,十一五队列都高于CCSC。在男性人群中,脑卒中、缺血性脑卒中以及出血性脑卒中的标化死亡率均为十一五队列高于CCSC。在女性人群中脑卒中以及出血性脑卒中的标化死亡率为CCSC高于十一五队列,而缺血性脑卒中的标化死亡率在两个队列中基本一致。
CCSC中,按照指南分为四组,与对照组相比,多因素调整后,TC在5.18-5.68mmol/L(200-219mg/d1)以及>6.22mmol/L(240mg/d1)组缺血性脑卒中的发病风险分别增加55%和77%,致死性缺血性脑卒中的发生风险分别增加99%和131%(均P<0.05)。TC水平每升高1mmol/L,缺血性脑卒中和致死性缺血性脑卒中的发病风险分别增加21%和25%(均P<0.05)。十一五队列中,按照指南分为四组,与对照组相比,多因素调整后,TC在各水平组发生脑卒中、缺血性脑卒中和出血性脑卒中风险的HR值均没有统计学意义(均P>0.05)。
两个队列合并的分析结果显示,按照指南分为四组,与对照组相比,多因素调整后,TC在各水平组缺血性脑卒中的发病风险分别增加31%、45%和61%(均P<0.05)；TC在5.18-5.68mmol/L(200-219mg/d1)和≥6.22mmol/L(240mg/d1)组发生致死性缺血性脑卒中的风险分别增加80%和131%(均P<0.05)。多因素调整后,TC水平每升高1mmol/L,脑卒中的发病风险增加5%,缺血性脑卒中的发病风险增加20%,致死性缺血性脑卒中的发生风险增加24%,均P<0.05。PARP分析结果显示,脑卒中的发病3.6%可归因于TC水平升高,缺血性脑卒中的发病11.1%可归因于TC水平升高。亚组分析结果显示,多因素调整后,TC水平每升高1mmol/L,缺血性脑卒中的发病风险在男性和女性人群中分别增加20%和17%；在年龄<60岁和≥60岁人群中分别增加18%和19%；在SBP<140mmHg和≥140mmHg人群中分别增加14%和25%；在吸烟和不吸烟人群中分别增加17%和21%(均P<0.05)。与对照组相比,多因素调整后,在男性、年龄<60岁、SBP≥140mmHg和吸烟人群中,TC在5.69-6.21(220-239)和≥6.22mmol/L(240mg/d1)组缺血性脑卒中的发病风险均显著增加；在SBP≥140mmHg人群中,TC≥6.22mmol/L(240mg/d1)组脑卒中的发病风险增加32%(P=0.01)；在吸烟人群中,TC≥6.22mmol/L(240mg/d1)组脑卒中和出血性脑卒中的发病风险分别增加33%(P=0.02)和50%(P=0.04)。此外,合并其他危险因素时,随着危险因素数目的增加,脑卒中及其亚型的发病风险均增加。在相同危险因素条件下,与TC<5.18mmol/L(200mg/d1)者相比,TC≥5.18mmol/L(200mg/d1)的个体脑卒中及其亚型的发病风险均增加。
结论：
近二三十年来,中国人群TC水平呈现升高的趋势。脑卒中、缺血性脑卒中和出血性脑卒中的发病率也不断增加。随着TC水平的增加,脑卒中和缺血性脑卒中的发病风险均不断增加,致死性缺血性脑卒中的风险也显著增加。吸烟人群中,与TC<5.18mmol/L(200mg/d1)组相比,TC>6.22mmol/L(240mg/d1)组出血性脑卒中的发病风险显著增加。合并其他危险因素时,在相同危险因素条件下,高TC水平者脑卒中、缺血性脑卒中和出血性脑卒中的发病风险均增加。鉴于我国人群TC水平和脑卒中发病率不断升高,及TC水平对脑卒中及其亚型发病的危险性,通过平衡膳食,提倡健康生活方式,减少血脂紊乱和降低人群血清TC水平,是减少与控制我国人群脑卒中发病率和危害的重要公共卫生策略和措施之一。
背景与目的：
既往研究发现脂联素可以调节糖代谢以及脂质代谢,并具有抗炎以及抗动脉粥样硬化的作用。这些结果提示脂联素可能具有降低冠心病发病风险的作用。此外,许多研究探讨了脂联素基因(ADIPOQ)单核苷酸多态性,即+45T>G(rs2241766),+276G>T(rs1501299)以及-11377C>G(rs266729),与心血管疾病风险的关系,然而这些研究并没有得到一致的结果。本研究拟通过meta分析评价ADIPOQ三个多态位点与心血管疾病风险的相关性,并且通过对脂联素水平与冠心病发病关系的前瞻性研究资料进行meta分析,以评估脂联素水平对冠心病发病风险的影响。资料与方法：
两名评价者独立系统检索Pubmed、EMbase、CBM、维普、万方等数据库,获取ADIPOQ三个多态位点与心血管疾病风险的关联研究文献,以及脂联素水平与冠心病关系的前瞻性研究文献。在2012年2月之前发表的研究被纳入进行meta分析。本研究中,ADIPOQ与心血管疾病的meta分析主要考虑病例对照组之间等位基因频率比较的比值比(Odds Ratio,OR值)；脂联素与冠心病的1neta分析主要提取各研究的多因素调整的相对风险度(RR)及95%置信区间(95%CI)等数据。采用Q检验及I2统计量评估研究间的异质性,根据异质性选择固定效应或随机效应模型合并RR值或OR值及95%CI；使用Egger线性回归检验估计发表偏倚。本研究使用相关评分标准对所有纳入的研究进行评分。
结果：
ADIPOQ三个多态位点与心血管疾病风险的meta分析纳入37个病例对照研究,包含6,398个病例和10,829个对照(rs2241766)；8,392个病例和18,730个对照(rs1501299)；以及7,835个病例和14,023个对照(rs266729)。三个多态位点都与心血管疾病存在显著关联。合并OR值分别为：rs2241766,1.22(95%CI：1.07,1.39；P=0.004)；rs1501299,0.90(95%CI：0.83,0.97；P=0.007)；rs266729,1.09(95%CI：1.01,1.17；P=0.032)。rs2241766和rs1501299与冠心病也显著相关,合并OR值分别为1.29(95%CI：1.09,1.52；P=0.004)和0.89(95%CI：0.81,0.99；P=0.025)。rs2241766和rs266729与脑卒中存在显著关联。固定效应模型合并OR值分别为1.28(95%CI：1.12,1.46；P<0.0001)和1.20(95%CI：1.08,1.34；P=0.0001)。三个位点与高血压之间关联都没有统计学显著性。分析发现纳入的研究间存在显著异质性。对rs266729与CVD之间的关系按照种族进行亚组分析可以消除异质性,欧洲和亚洲人群亚组分析的I2分别为26.1%和O。亚组分析发现只有在亚洲人群中的相关性是显著的,合并OR值(固定效应模型)为1.29(95%CI：1.18,1.42；P<0.001)；在欧洲人群中相关性并不显著,合并OR值(固定效应模型)为1.01(95%CI：0.94,1.08；P=0.880)。分析中发现rs2241766与CVD关系的研究存在发表偏倚(Egger's检验,P=0.007)。
脂联素水平与冠心病meta分析共纳入12个前瞻性研究,其中包括8个巢式病例对照研究和4个队列研究。最终共有11,461名研究对象纳入分析,其中4,132名研究对象发生冠心病。结果显示脂联素水平与冠心病的发病风险呈负相关。合并的RR值为0.83(95%CI：0.69,0.98；P=0.031)。亚组分析结果显示在男性、女性以及年龄小于65岁的群体中都存在这种负相关性。本项研究中没有发现发表偏倚(P=0.911)。
结论：
本项meta分析显示ADIPOQ基因单核苷酸多态性与心血管疾病之间存在显著的相关性。脂联素水平对冠心病的发生具有保护作用。我们仍然需要高质量的大规模研究来证实这些相关性。
Background and Objective:
Stroke is the most common cause of death and severe disability in the world. The relationships between serum total cholesterol (TC) level and risk of stroke and its subtypes are not well established in Asia. We used individual data from the cohorts of China Cohort Studies Collaboration (CCSC) and the Incidence and Comprehensive Control of Metabolic Syndrome Study (ICMS) to explore the impact of baseline TC level on the risks of total stroke, ischaemic and haemorrhagic stroke and its implication in the population prevention of stroke in China.
Materials and Methods:
A total of62,603participants from CCSC were included, of which data on cholesterol levels at baseline and the outcome of stroke at follow-up were all available. For ICMS, of27,020participants aged35to74at baseline,21,556participants have completed the follow-up survey and19,796participants with full information were analyzed in this study. Participants in these two cohorts were divided into four groups according to the baseline TC level, that was TC<5.18mmol/L (200mg/dl),5.18-5.67mmol/L (200-219mg/dl),5.68-6.21mmol/L (220-239mg/dl) and>6.22mmol/L (240mg/dl). The differences of mean levels of baseline risk factors were compared. Cox regression models were used to estimate the hazard ratios (HR) and95%confidence intervals (CI) for the incidence and death of stroke and stroke subtypes. Population attributable risk percentage (PARP) was also calculated.
Results:
Over the course of573,894.92person-years of follow-up in CCSC, a total of1,068incident strokes were collected, including367ischaemic strokes,361haemorrhagic strokes and340unclassified strokes. For ICMS, after156,306.26person-years of follow-up, a total of400incident strokes were collected, including227ischaemic strokes,148haemorrhagic strokes and25unclassified strokes.
The age-adjusted mean level of baseline TC in ICMS participants was0.23mmol/L (8.88mg/dl) higher than that of CCSC participants. The age-standardized person-year incidence of stroke, ischaemic and haemorrhagic stroke were all higher for both men and women in ICMS. In male subgroup analysis, the standardized person-year mortality of stroke, ischaemic stroke and haemorrhagic stroke were all higher in men from ICMS compared with that in men from CCSC. However, the age-standardized person-year mortality of stroke and haemorrhagic stroke were higher in CCSC in women. The age-standardized person-year mortality of ischaemic stroke was basically the same in both CCSC and ICMS in women.
In CCSC, the multivariate-adjusted HRs (95%CIs) for total (fatal or nonfatal) ischemic stroke were1.55(1.17,2.06) and1.77(1.27,2.45) in TC5.18-5.68mmol/L (200-219mg/dl) and TC>6.22mmol/L (240mg/dl) groups compared with the lowest baseline TC level group, respectively. Accordingly, compared with the lowest baseline TC level group, the multivariate-adjusted HRs (95%CIs) for fatal ischemic stroke were1.99(1.22,3.24) and2.31(1.31,4.08) in TC5.18-5.68mmol/L (200-219mg/dl) and TC>6.22mmol/L (240mg/dl) groups, respectively. Each1-mmol/L increase in TC was associated with a21%greater risk of total ischemic stroke (P<0.0001). In ICMS cohort, the multivariate-adjusted HRs for stroke, ischaemic and haemorrhagic stroke were not statistically significant in TC5.18-5.68mmol/L (200-219mg/dl),5.69-6.21mmol/L (220-239mg/dl) and TC>6.22mmol/L (240mg/dl) groups compared with the lowest TC group.
For the combined data of CCSC and ICMS, the multivariate-adjusted HRs (95%CIs) for total ischemic stroke were1.31(1.04,1.65),1.45(1.10,1.91) and1.61(1.24,2.08) in TC5.18-5.68mmol/L (200-219mg/dl),5.69-6.21mmol/L (220-239mg/dl) and TC>6.22mmol/L (240mg/dl) groups compared with the lowest TC group, separately. The multivariate-adjusted HRs (95%CIs) for fatal ischemic stroke were correspondingly1.80(1.16,2.79) and2.31(1.42,3.75) in TC5.18-5.68(200-219) and TC≥6.22mmol/L (240mg/dl) groups. Each1-mmol/L increase in TC was significantly associated with a5%,20%and24%higher risk of total stroke, total ischemic stroke and fatal ischemic stroke, respectively. PARP for total stroke and total ischemic stroke was3.6%and11.1%, respectively.
The results of subgroup analyses showed that each1-mmol/L increase in TC was significantly associated with a20%higher risk of ischemic stroke for men and17%for women,18%for age<60and19%for age>60,14%for SBP<140mmHg and25%for SBP≥140mmHg, and17%for smokers and21%for never smokers. The multivariate adjusted risk of ischemic stroke was significantly increased in TC5.69-6.21(220-239) and≥6.22mmol/L (240mg/dl) for men, age<60, SBP≥140mmHg and smoker subgroups compared with the reference group. The multivariate-adjusted HR (95%CI) for stroke was1.32(1.06,1.65) in TC>6.22mmol/L (240mg/dl) group for SBP>140mmHg subgroup accordingly. In smokers, the multivariate-adjusted HRs (95%CIs) for total stroke and total haemorrhagic stroke were1.33(1.05,1.69) and1.50(1.01,2.22), respectively. Besides, an elevated HR of total stroke and its subtypes were found when considering TC with the increased number of other risk factors.
Conclusions:
In the three decades, the serum TC level in Chinese populations significantly increased, so as the incidence of stroke, ischaemic and haemorrhagic stroke in China. The baseline TC level was strongly associated with the risks of stroke and ischaemic stroke in our study. For smokers, the risk of total stroke and total haemorrhagic stroke significantly increased in TC>6.22mmol/L (240mg/dl) compared with TC<5.18mmol/L (200mg/dl). Higher TC levels were strongly associated with increased risks of stroke, ischaemic and haemorrhagic stroke.Reducing serum TC level in residents through primary prevention and lifestyle modification will have an important impact on population prevention and control of stroke in China.
Background and Objective:
Adiponectin is the most abundant circulating protein secreted by adipocytes. Previous studies have examined the associations between polymorphisms of adiponectin gene (ADIPOQ) and cardiovascular disease (CVD), but those studies have been inconclusive. There is also uncertainty about the association between concentrations of circulating adiponectin and coronary heart disease (CHD) risk. The aims of this study were to evaluate the relationship between three single nucleotide polymorphisms (SNPs),+45T>G (rs2241766),+276G>T (rs1501299) and-11377C
A comprehensive search was conducted to identify all studies on the association of ADIPOQ gene polymorphisms with CVD risk and the association of adiponectin levels with incident risk of CHD. The fixed and random effect pooled measures (i.e. odds ratio (OR) and95%confidence interval (CI)) were calculated in the meta-analysis. Heterogeneity among studies was evaluated using Q test and the I2. Publication bias was estimated using modified Egger's linear regression test.
Results:
Thirty-seven studies concerning the associations between the three polymorphisms of ADIPOQ gene and CVD risk were enrolled in this meta-analysis, including6,398cases and10,829controls for rs2241766,8,392cases and18,730controls for rs1501299and7,835cases and14,023controls for rs266729. The three SNPs were significantly associated with CVD, yielding pooled ORs of1.22(95%CI:1.07,1.39; P=0.004),0.90(95%CI:0.83,0.97; P=0.007) and1.09(95%CI:1.01,1.17; P=0.032) for rs2241766, rs1501299and rs266729, respectively. Rs2241766and rs1501299were significantly associated with coronary heart disease (CHD), yielding pooled ORs of1.29(95%CI:1.09,1.52; P=0.004) and0.89(95%CI:0.81,0.99; P=0.025), respectively. The pooled OR for rs266729and CHD was1.09(95%CI:0.99,1.19; P=0.090). Rs2241766and rs266729were significantly associated with stroke, yielding pooled ORs (fixed-effects method) of1.28(95%CI:1.12,1.46; P<0.0001) and1.20(95%CI:1.08,1.34; P=0.0001), respectively. The associations between the three SNPs and hypertension were not significant. Significant between-study heterogeneity and evidence of publication bias were observed in the meta-analysis.
Twelve prospective studies comprising8nested case-control studies and4cohort studies were included in the meta-analysis. A total of14,960participants were enrolled and4,132incident CHD events were observed. The pooled RR of CHD was0.83(95%CI:0.69,0.98; P=0.031). The inverse association was consistently observed in men and women and in the studies with mean age<65year. No publication bias was found in our study (P=0.911).
Conclusions:
The present meta-analysis showed that the associations between rs2241766, rs1501299and rs266729in the ADIPOQ and CVD were significant. Higher levels of adiponectin were associated with a low risk of CHD. The protective effect was consistent in men and women and in the middle-aged populations. High quality studies are still needed to confirm the associations.
引文
1. World Health Organization. World Health Report 2003. Shaping the future. World Health Organization:Geneva.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke[J]. Lancet,2008, 371(9624):1612-1623.
3. 吴兆苏,姚崇华,赵冬,等.我国多省市心血管病趋势及决定因素的人群监测(中国MONICA方案)Ⅰ：发病率和死亡率监测结果[J].中华心血病杂志,1997,25(1)：6-11.
4. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES Ⅱ mortality study [J]. Am J Hypertens,2007,20(3):338-341.
5. Tunick PA, Kronzon I. Primary prevention of ischemic stroke[J]. Circulation, 2001,104(11):E59.
6. Michael KM, Shaughnessy M. Stroke prevention and management in older adults[J]. J Cardiovasc Nurs,2006,21(5 Suppl 1):S21-26.
7. Sacco RL. Newer risk factors for stroke[J]. Neurology,2001,57(5 Suppl 2):S31-34.
8. Wannamethee SG, Shaper AG, Ebrahim S. HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men[J]. Stroke,2000, 31(8):1882-1888.
9. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial[J]. N Engl J Med,1989,320(14):904-910.
10. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study [J]. BMJ,2006, 333(7557):22.
11. Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, Tsugane S. High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population:The JPHC study [J]. Atherosclerosis,2012,15(1):19-22.
12. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Sivenius J, Benetou V, Tuomilehto J, Koudstaal PJ et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE:a collaborative study among research centres in Europe[J]. J Epidemiol Community Health,2002,56 Suppl 1:ⅰ19-24.
13. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity [J]. JAMA,2000,284(3):311-318.
14. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group[J]. Arch Intern Med,1992,152(1):56-64.
15. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study[J]. JAMA,1995,274(2):131-136.
16. Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age[J]. Ann Intern Med,2001, 134(6):433-439.
17. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions:The Atherosclerosis Risk in Communities (ARIC) Study [J]. Circulation,2001,104(10):1108-1113.
18. Landau WM. Is cholesterol a risk factor for stroke?:No[J]. Arch Neurol,1999, 56(12):1521-1524.
19. Qizilbash N. Are risk factors for stroke and coronary disease the same?[J]. Curr Opin Lipidol,1998,9(4):325-328.
20. Demchuk AM, Hess DC, Brass LM, Yatsu FM. Is cholesterol a risk factor for stroke?:Yes[J]. Arch Neurol,1999,56(12):1518-1520.
21. Canoui-Poitrine F, Luc G, Bard JM, Ferrieres J, Yarnell J, Arveiler D, Morange P, Kee F, Evans A, Amouyel P, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke:the PRIME Study[J]. Cerebrovasc Dis,2010,30(3):252-259.
22. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke[J]. Stroke,2003,34(12):2930-2934.
23. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cholesterol and haemorrhagic stroke in men:Korea Medical Insurance Corporation Study [J]. Lancet,2001,357(9260):922-925.
24. Suzuki K, Izumi M, Sakamoto T, Hayashi M. Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan[J]. Cerebrovasc Dis,2011,31(1):100-106.
25. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region[J]. Int J Epidemiol,2003,32(4):563-572.
26. Cholesterol, diastolic blood pressure, and stroke:13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration[J]. Lancet, 1995,346(8991-8992):1647-1653.
27. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure:a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths[J]. Lancet,2007,370(9602):1829-1839.
28. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group[J]. Lancet,1998, 352(9143):1801-1807.
29.王薇,赵冬,刘静,等.中国35-64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2006,34(2)：169-173.
30. 江滨,方向华,刘运海,等.总胆固醇及甘油三酯与卒中亚型关系的前瞻性研究[J].中华心血管病杂志,2010,38(3)：268-271.
31. Zhang LF, Yang J, Hong Z, Yuan GQ Zhou BF, Zhao LC, Huang YN, Chen J, Wu YF. Proportion of different subtypes of stroke in China[J]. Stroke,2003, 34(9):2091-2096.
32. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes:initial findings from the North East Melbourne stroke incidence study (NEMESIS)[J]. Stroke,2001,32(8):1732-1738.
33. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamatelopoulos S. Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry[J]. Stroke,1999,30(2):363-370.
34. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of stroke in Germany--the Erlangen Stroke Project (ESPro):incidence and case fatality at 1,3, and 12 months[J]. Stroke, 1998,29(12):2501-2506.
35. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types:results from an international collaboration. International Stroke Incidence Collaboration[J]. Stroke,1997,28(3):491-499.
36. Woodward M, Barzi F, Martiniuk A, Fang X, Gu DF, Imai Y, Lam TH, Pan WH, Rodgers A, Suh I, et al. Cohort profile:the Asia Pacific Cohort Studies Collaboration[J]. Int J Epidemiol,2006,35(6):1412-1416.
37. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease):a major international collaboration. WHO MONICA Project Principal Investigators [J]. J Clin Epidemiol,1988, 41(2):105-114.
38. 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-419.
39. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults:findings from the National Health and Nutrition Examination Survey,1999 to 2000[J]. Circulation,2003,107(17):2185-2189.
40. 赵冬.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志,2003,24(3)：236-239.
41. Zhang Y, Tuomilehto J, Jousilahti P, Wang Y, Antikainen R, Hu G. Total and High-Density Lipoprotein Cholesterol and Stroke Risk[J]. Stroke,2012, PMID: 22496337
42. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project[J]. Stroke,2002,33(7):1863-1868.
43. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, JM G. Lipid levels and the risk of ischemic stroke in women[J]. Neurology,2007,68(8):556-562.
44. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, Rao X, Zhou B, Detrano R, Liu K. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation,2006,114(21):2217-2225.
45. 武阳丰,周北凡,李莹等.缺血性心血管疾病：一个反映血脂异常潜在危险的新指标[J].中华心血管病杂志,2004,32(2)：173-176.
46. 中国心血管病流行病学多中心研究专题协作组.90年代初期我国心血管病的总体形势与特点[J].中国慢性病预防与控制,1996,14(4)：145-149.
47. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y Sino-MONICA project:a collaborative study on trends and determinants in cardiovascular diseases in China, Part i:morbidity and mortality monitoring[J]. Circulation, 2001,103(3):462-468.
48. Ueshima H, Choudhury SR, Okayama A, Hayakawa T, Kita Y, Kadowaki T, Okamura T, Minowa M, Iimura O. Cigarette smoking as a risk factor for stroke death in Japan:NIPPON DATA80[J]. Stroke,2004,35(8):1836-1841.
49. Feigin V, Parag V, Lawes CM, Rodgers A, Suh I, Woodward M, Jamrozik K, Ueshima H. Smoking and elevated blood pressure are the most important risk factors for subarachnoid hemorrhage in the Asia-Pacific region:an overview of 26 cohorts involving 306,620 participants[J]. Stroke,2005,36(7):1360-1365.
50. Yamagishi K, Iso H, Kitamura A, Sankai T, Tanigawa T, Naito Y, Sato S, Imano H, Ohira T, Shimamoto T. Smoking raises the risk of total and ischemic strokes in hypertensive men[J]. Hypertens Res,2003,26(3):209-217.
51. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S. Blood pressure and cardiovascular disease in the Asia Pacific region[J]. J Hypertens,2003,21(4):707-716.
1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes[J]. J Biol Chem, 1995,270(45):26746-26749.
2. Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond[J]. Horm Metab Res,2002,34(9):469-474.
3. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity[J]. J Biol Chem,2003,278(11):9073-9085.
4. Lacquemant C, Froguel P, Lobbens S, Izzo P, Dina C, Ruiz J. The adiponectin gene SNP+45 is associated with coronary artery disease in Type 2 (non-insulin-dependent) diabetes mellitus[J]. Diabet Med,2004,21(7):776-781.
5. Qi L, Li T, Rimm E, Zhang C, Rifai N, Hunter D, Doria A, Hu FB. The+276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men[J]. Diabetes,2005,54(5):1607-1610.
6. Chiodini BD, Specchia C, Gori F, Barlera S, D'Orazio A, Pietri S, Crociati L, Nicolucci A, Franciosi M, Signorini S et al. Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes:an association study in an Italian population[J]. Ther Adv Cardiovasc Dis,2010, 4(4):223-230.
7. Leu HB, Chung CM, Lin SJ, Jong YS, Pan WH, Chen JW. Adiponectin gene polymorphism is selectively associated with the concomitant presence of metabolic syndrome and essential hypertension[J]. PLoS One,2011, 6(5):e19999.
8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia[J]. J Clin Endocrinol Metab,2001,86(5):1930-1935.
9. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men[J]. Metabolism, 2004,53(5):589-593.
10. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, et al. Hypoadiponectinemia is an independent risk factor for hypertension[J]. Hypertension,2004,43(6):1318-1323.
11. Bacci S, Menzaghi C, Ercolino T, Ma X, Rauseo A, Salvemini L, Vigna C, Fanelli R, Di Mario U, Doria A, et al. The+276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients[J]. Diabetes Care,2004,27(8):2015-2020.
12. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men[J]. JAMA,2004, 291(14):1730-1737.
13. Prior SL, Jones DA, Gill GV, Bain SC, Stephens JW. Association of the adiponectin rs266729 C>G variant and coronary heart disease in the low risk 'Golden Years' type 1 diabetes cohort[J]. Diabetes Res Clin Pract,2011, 91(3):e71-74.
14. Oguri M, Kato K, Yokoi K, Itoh T, Yoshida T, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, et al. Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome[J]. Atherosclerosis, 2009,206(2):486-493.
15. Hegener HH, Lee IM, Cook NR, Ridker PM, Zee RY Association of adiponectin gene variations with risk of incident myocardial infarction and ischemic stroke:a nested case-control study[J]. Clin Chem,2006, 52(11):2021-2027.
16. Leu HB, Chung CM, Chuang SY, Bai CH, Chen JR, Chen JW, Pan WH. Genetic variants of connexin37 are associated with carotid intima-medial thickness and future onset of ischemic stroke[J]. Atherosclerosis,2011, 214(1):101-106.
17. Liu F, He Z, Deng S, Zhang H, Li N, Xu J. Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population[J]. Mol Biol Rep,2011,38(3):1983-1988.
18. Ong KL, Li M, Tso AW, Xu A, Cherny SS, Sham PC, Tse HF, Lam TH, Cheung BM, Lam KS. Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese[J]. Eur J Endocrinol,2010,163(2):251-257.
19. Yamada Y, Kato K, Oguri M, Yoshida T, Yokoi K, Watanabe S, Metoki N, Yoshida H, Satoh K, Ichihara S, et al. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome[J]. Int J Mol Med,2008,21(6):801-808.
20. Yan WL, Chen SF, Huang JF, Shen Y, Qiang BQ, Liu DH, Gu DF. Common SNPs of APM1 gene are not associated with hypertension or obesity in Chinese population[J]. Biomed Environ Sci,2006,19(3):179-184.
21. 陈小良,程锦泉,张仁利,刘建平,李晓霞,童叶青,耿艺介.脂联素基因多态性与北方汉族人群缺血陛脑卒中易感性关系研究[J].中华流行病学杂志,2010,31(2)：129-132.
22. 贾玫,乔博明,张正,冯秀玲,秦效英,孙媛媛.脂联素启动子基因多态性和脂联素水平与高血压及并发症的相关性研究[J].中国实验诊断学,2008,12(2)：222-226.
23. 李晓霞,关红军,郭毓鹏,陈小良,杨印东,周君,程锦泉,聂绍发.脂联素基因多态性与缺血性脑卒中关系[J].中国公共卫生,2009,25(11)：1341-1343.
24. 唐晓明,李洁琪,吴立荣,庄梅,吕贞.脂联素基因+45T/G多态性与原发性高血压相关性的研究[J].天津医药,2008,36(10)：762-764.
25. 王忠莉,夏冰,姜黎,胡正国,曹萍.脂联素基因多态性与原发性高血压的关系[J].医学新知杂志,2008,18(1)：25-29.
26. 张子波,于丽军,杨康鹃,徐良慰,盛天昕,郝萍,王玉萍,孟繁平.延边朝鲜族和汉族脂联素启动子SNPs与原发性高血压的相关性[J].遗传,2011,33(1)：54-59.
27. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, et al. Disruption of adiponectin causes insulin resistance and neointimal formation[J]. J Biol Chem,2002, 277(29):25863-25866.
28. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, et al. Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin[J]. Circulation,1999,100(25):2473-2476.
29. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages[J]. Blood, 2000,96(5):1723-1732.
30. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway[J]. Circulation,2000,102(11):1296-1301.
31. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages[J]. Circulation, 2001,103(8):1057-1063.
32. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell[J]. Circulation,2002,105(24):2893-2898.
33. Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers[J]. Eur Heart J,2005,26(16):1640-1646.
34. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Sakamoto T, Yoshimura M, Kimura K, Umemura S, Ogawa H. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men[J]. Circ J,2007,71(11):1703-1709.
35. Koz C, Uzun M, Yokusoglu M, Baysan O, Erinc K, Sag C, Hasimi A, Isik E. Evaluation of plasma adiponectin levels in young men with coronary artery disease[J]. Acta Cardiol,2007,62(3):239-243.
36. Lu G, Chiem A, Anuurad E, Havel PJ, Pearson TA, Ormsby B, Berglund L. Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity[J]. Transl Res,2007,149(6): 317-323.
37. Zhang BC, Liu WJ, Che WL, Xu YW. Serum Total Adiponectin Level and Risk of Cardiovascular Disease in Han Chinese Populations:A Meta-Analysis of 17 Case-Control Studies[J]. Clin Endocrinol (Oxf),2011, doi:10.1111/j. 1365-2265.2011.04260.ⅹ.
38. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women[J]. Atherosclerosis,2011,219(1):322-329.
39. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women[J]. J Clin Endocrinol Metab, 2005,90(10):5677-5683.
40. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women[J]. J Clin Endocrinol Metab, 2008,93(9):3357-3364.
41. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA,2000,283(15): 2008-2012.
42. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, et al. Replicating genotype-phenotype associations[J]. Nature,2007,447(7145):655-660.
43. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses.Available from:URL:http://www.ohri.ca/programs/ clinical_epidemiology/oxford.htm [cited 2011 Sep 19].
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses[J]. BMJ,2003,327(7414):557-560.
45. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ,1997,315(7109):629-634.
46. DerSimonian R, Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials, 1986,7(3):177-188.
47. Ioannidis JP, Trikalinos TA. Early extreme contradictory estimates may appear in published research:the Proteus phenomenon in molecular genetics research and randomized trials[J]. J Clin Epidemiol,2005,58(6):543-549.
48. Qi L, Doria A, Manson JE, Meigs JB, Hunter D, Mantzoros CS, Hu FB. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes[J]. Diabetes,2006,55(5):1512-1516.
49. Sun K, Li Y, Wei C, Tong Y, Zheng H, Guo Y. Recessive protective effect of ADIPOQ rs1501299 on cardiovascular diseases with type 2 diabetes:A meta-analysis[J]. Mol Cell Endocrinol,2012,349(2):162-169.
50. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women[J]. Atherosclerosis,2011,219(1):322-329.
51. Siitonen N, Pulkkinen L, Lindstrom J, Kolehmainen M, Eriksson JG, Venojarvi M, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations:the Finnish Diabetes Prevention Study [J]. BMC Med Genet,2011,12:5.
52. Hivert MF, Manning AK, McAteer JB, Florez JC, Dupuis J, Fox CS, O'Donnell CJ, Cupples LA, Meigs JB. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits:the Framingham Offspring Study [J]. Diabetes,2008,57(12):3353-3359.
53. Kyriakou T, Collins LJ, Spencer-Jones NJ, Malcolm C, Wang X, Snieder H, Swaminathan R, Burling KA, Hart DJ, Spector TD, et al. Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity [J]. J Hum Genet,2008, 53(8):718-727.
54. Richards JB, Waterworth D, O'Rahilly S, Hivert MF, Loos RJ, Perry JR, Tanaka T, Timpson NJ, Semple RK, Soranzo N, et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels[J]. PLoS Genet,2009,5(12):e1000768.
55. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease[J]. Diabetes, 2007,56(5):1198-1209.
56. Gong M, Long J, Liu Q, Deng HC. Association of the ADIPOQ rs 17360539 and rs266729 polymorphisms with type 2 diabetes:a meta-analysis[J]. Mol Cell Endocrinol,2010,325(1-2):78-83.
57. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls[J]. Br J Clin Pharmacol,2001,52(5): 489-499.
58. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome[J]. J Clin Invest,2006,116(7):1784-1792.
59. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HE Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30)[J]. J Biol Chem,2002, 277(33):29359-29362.
60. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, Kawamoto T, Matsumoto S, Nagaretani H, Kumada M, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease[J]. J Am Coll Cardiol,2004,43(7):1195-1200.
61. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, et al. Adiponectin in renal disease:relationship to phenotype and genetic variation in the gene encoding adiponectin[J]. Kidney Int,2004,65(1):274-281.
62. Filippi E, Sentinelli F, Romeo S, Area M, Berni A, Tiberti C, Verrienti A, Fanelli M, Fallarino M, Sorropago G, et al. The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age 63. Ru Y MM, M T, Wang CJ, Wang YM, Zhang Q, Chen MW, Yang MG. Relations of Adiponectin Gene SNP276 With Coronary Heart Disease and Insulin Sensitivity.[J]. Chinese circulation journal,2005,20(5):332-335.
64. Gable DR, Matin J, Whittall R, Cakmak H, Li KW, Cooper J, Miller GJ, Humphries SE. Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects[J]. Ann Hum Genet,2007,71(Pt 4):453-466.
65. Wang JN LS. Adiponectin gene polymorphism in han people of Jilin region and its association with coronary heart disease[J]. Chinese Journal of Laboratory Diagnosis,2006,10(11):1272-1274.
66. Jung CH, Rhee EJ, Kim SY, Shin HS, Kim BJ, Sung KC, Kim BS, Lee WY, Kang JH, Oh KW, et al. Associations between two single nucleotide polymorphisms of adiponectin gene and coronary artery diseases[J]. Endocr J, 2006,53(5):671-677.
67. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D, Rimm EB. Single nucleotide polymorphisms at the adiponectin locus and risk of coronary heart disease in men and women[J]. Obesity (Silver Spring),2007, 15(8):2051-2060.
68. Lu f WL, Yang ZJ, Zhu TB, Wang ZG, Zhu HJ, Tang NP, Cao KJ, Huang J, Gui M. Correlation between single nucleotide polymorphism(SNP+276 G/T) of adiponectin gene and coronary artery disease in non-diabetic population.[J]. Acta universitatis medicinalis nanjing,2007,27(7):736-739.
69. Liang XZ XJ, Wang J, Yu P, Qi WG, Ma L, Hu B, Luo Y, Zhang DF. Correlation between single nucleotide polymorphism (SNP+276G/T) of adiponectin gene and coronary artery disease[J]. Chinese Journal of Cardiovascular Review,2008,6(11):838-840.
70. Chang YC, Jiang JY, Jiang YD, Chiang FT, Hwang JJ, Lien WP, Chuang LM. Interaction of ADIPOQ genetic polymorphism with blood pressure and plasma cholesterol level on the risk of coronary artery disease[J]. Circ J,2009, 73(10):1934-1938.
71. Foucan L, Ezourhi N, Maimaitiming S, Hedreville S, Inamo J, Atallah A, Bangou-Bredent J, Aubert R, Chout R, Fumeron F, et al. Adiponectin multimers and ADIPOQ T45G in coronary artery disease in Caribbean type 2 diabetic subjects of African descent[J]. Obesity (Silver Spring),2010, 18(7):1466-1468.
72. Zhang XL PW, Lu L, Wu LiQ, Gu G, Wand LJ, Yan XX, Chen QJ, Shen WF. Correlation of adiponectin gene polymorphisms with coronary artery disease and plaque progression.[J]. Journal of shanghai jiaotong university (medical science),2009,29(4):435-439.
73. Zhong C, Zhen D, Qi Q, Genshan M. A lack of association between adiponectin polymorphisms and coronary artery disease in a Chinese population[J]. Genet Mol Biol,2010,33(3):428-433.
74. De Caterina R, Talmud PJ, Merlini PA, Foco L, Pastorino R, Altshuler D, Mauri F, Peyvandi F, Lina D, Kathiresan S, et al. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction [J]. Atherosclerosis,2011,214(2):397-403.
75. Xu L LW. Correlation of adiponectin gene SNP+45 T/G polymorphism with coronary heart disease[J]. Chinese Journal of Pathophysiology,2010, 26(6):1064-1068.
76. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Hussain T. Adiponectin gene variants and the risk of coronary artery disease in patients with type 2 diabetes[J]. Mol Biol Rep,2011,38(6):3703-3708.
77. Rodriguez-Rodriguez L, Garcia-Bermudez M, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA. Lack of association between ADIPOQ rs266729 and ADIPOQ rs 1501299 polymorphisms and cardiovascular disease in rheumatoid arthritis patients[J]. Tissue Antigens,2011,77(1):74-78.
78. Chen XL CH, Zhang RL, Liu JP, Li XX, Tong YQ, Geng YJ. Study on the relationship between polymorphism of adiponectin gene and risk of ischemic stroke among Han population in the Northern parts of China[J]. Chin J Epidemiol,2010,31(2):129-132.
79. Sabouri S, Ghayour-Mobarhan M, Moohebati M, Hassani M, Kassaeian J, Tatari F, Mahmoodi-kordi F, Esmaeili HA, Tavallaie S, Paydar R, et al. Association between 45T/G polymorphism of adiponectin gene and coronary artery disease in an Iranian population[J]. ScientificWorldJournal,2011, 11:93-101.
80. Esteghamati A, Mansournia N, Nakhjavani M, Mansournia MA, Nikzamir A, Abbasi M. Association of +45(T/G) and +276(G/T) polymorphisms in the adiponectin gene with coronary artery disease in a population of Iranian patients with type 2 diabetes[J]. Mol Biol Rep,2012,39(4):3791-3797.
81. Boumaiza I, Omezzine A, Rejeb J, Rebhi L, Ben Rejeb N, Nabli N, Ben Abdelaziz A, Boughzala E, Bouslama A. Single-nucleotide polymorphisms at the adiponectin locus and risk of coronary artery disease in Tunisian coronaries[J]. J Cardiovasc Med (Hagerstown),2011,12(9):619-624.
82. Katakami N, Kaneto H, Matsuoka TA, Takahara M, Maeda N, Shimizu I, Ohno K, Osonoi T, Kawai K, Ishibashi F, et al. Adiponectin G276T gene polymorphism is associated with cardiovascular disease in Japanese patients with type 2 diabetes[J]. Atherosclerosis,220(2):437-442.
83. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, Yeh J, Best LG. Adiponectin and coronary heart disease:the Strong Heart Study [J]. Arteriosclerosis, thrombosis, and vascular biology,2005,25(3):e15-16.
84. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes[J]. Diabetes, 2005,54(2):534-539.
85. Kanaya AM, Wassel Fyr C, Vittinghoff E, Havel PJ, Cesari M, Nicklas B, Harris T, Newman AB, Satterfield S, Cummings SR. Serum adiponectin and coronary heart disease risk in older Black and White Americans[J]. J Clin Endocrinol Metab,2006,91(12):5044-5050.
86. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH. Adiponectin and coronary heart disease:a prospective study and meta-analysis[J]. Circulation,2006,114(7):623-629.
87. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men:results from the 18-year follow-up of a large cohort from southern Germany [J]. J Am Coll Cardiol, 2006,48(7):1369-1377.
88. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality:the Rancho Bernardo study[J]. Am J Epidemiol,2007,165(2):164-174.
89. Hatano Y, Matsumoto M, Ishikawa S, Kajii E. Plasma adiponectin level and myocardial infarction:the JMS Cohort Study[J]. J Epidemiol,2009, 19(2):49-55.
90. Cote M, Cartier A, Reuwer AQ, Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Kastelein JJ, Boekholdt SM, Khaw KT. Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study)[J]. Am J Cardiol,2011, 108(3):367-373.
91. Kanaya AM, Fyr CW, Vittinghoff E, Havel PJ, Cesari M, Nicklas B, Harris T, Newman AB, Satterfield S, Cummings SR. Serum adiponectin and coronary heart disease risk in Older Black and White Americans[J]. Journal of Clinical Endocrinology and Metabolism,2006,91(12):5044-5050.
1. World Health Organization. World Health Report 2003. Shaping the future. World Health Organization:Geneva.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke[J]. Lancet,2008, 371(9624):1612-1623.
3. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y. Sino-MONICA project:a collaborative study on trends and determinants in cardiovascular diseases in China, Part ⅰ:morbidity and mortality monitoring [J]. Circulation, 2001,103(3):462-468.
4. 赵冬.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志,2003,24(3)：236-239.
5. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, et al. Major causes of death among men and women in China[J]. N Engl J Med,2005,353(11):1124-1134.
6. 吴兆苏,姚崇华,赵冬,等.我国多省市心血管病趋势及决定因素的人群监测(中国MONICA方案)Ⅰ：发病率和死亡率监测结果[J].中华心血病杂志,1997,25(1)：6-11.
7. Carallo C, Lucca LF, Ciamei M, Tucci S, de Franceschi MS. Wall shear stress is lower in the carotid artery responsible for a unilateral ischemic stroke[J]. Atherosclerosis,2006,185(1):108-113.
8. Birchall D, Zaman A, Hacker J, Davies G, Mendelow D. Analysis of haemodynamic disturbance in the atherosclerotic carotid artery using computational fluid dynamics[J]. Eur Radiol,2006,16(5):1074-1083.
9. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study[J]. Am J Hypertens,2007, 20(3):338-341.
10. Michael KM, Shaughnessy M. Stroke prevention and management in older adults[J]. J Cardiovasc Nurs,2006,21(5 Suppl 1):S21-26.
11. Mozaffarian D, Fried LP, Burke GL, Fitzpatrick A, Siscovick DS. Lifestyles of older adults:can we influence cardiovascular risk in older adults?[J]. Am J Geriatr Cardiol,2004,13(3):153-160.
12. Nilsson PM. Reducing the risk of stroke in elderly patients with hypertension: a critical review of the efficacy of antihypertensive drugs [J]. Drugs Aging, 2005,22(6):517-524.
13. Redon J, Cea-Calvo L, Lozano JV, Marti-Canales JC, Llisterri JL, Aznar J, Gonzalez-Esteban J. Differences in blood pressure control and stroke mortality across Spain:the Prevencion de Riesgo de Ictus (PREV-ICTUS) study [J]. Hypertension,2007,49(4):799-805.
14. Tunick PA, Kronzon I. Primary prevention of ischemic stroke[J]. Circulation, 2001,104(11):E59.
15. Sacco RL. Newer risk factors for stroke[J]. Neurology,2001,57(5 Suppl 2):S31-34.
16. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity[J]. JAMA,2000,284(3):311-318.
17. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group[J]. Arch Intern Med,1992,152(1):56-64.
18. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study[J]. JAMA,1995, 274(2):131-136.
19. Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age[J]. Ann Intern Med,2001, 134(6):433-439.
20. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions:The Atherosclerosis Risk in Communities (ARIC) Study[J]. Circulation,2001,104(10):1108-1113.
21. Collaboration APCS. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region[J]. Diabetologia,2007,50(11):2289-2297.
22. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study [J]. BMJ,2006, 333(7557):22.
23. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure:a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths[J]. Lancet,2007, 370(9602):1829-1839.
24. Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, Tsugane S. High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population:The JPHC study[J]. Atherosclerosis,2012,15(1):19-22.
25. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region[J]. Int J Epidemiol,2003,32(4):563-572.
26. 王薇,赵冬,刘静,等.中国35-64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2006,34(2)：169-173.
27. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, Huang YN, Chen J, Wu YF. Proportion of different subtypes of stroke in China[J], Stroke,2003, 34(9):2091-2096.
28. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes:initial findings from the North East Melbourne stroke incidence study (NEMESIS)[J]. Stroke,2001,32(8):1732-1738.
29. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamatelopoulos S. Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry[J]. Stroke,1999,30(2):363-370.
30. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of stroke in Germany--the Erlangen Stroke Project (ESPro):incidence and case fatality at 1,3, and 12 months[J]. Stroke,1998,29(12):2501-2506.
31. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types:results from an international collaboration. International Stroke Incidence Collaboration[J]. Stroke,1997,28(3):491-499.
32. Zhang XF, Attia J, D'Este C, Yu XH, Wu XG. A risk score predicted coronary heart disease and stroke in a Chinese cohort[J]. J Clin Epidemiol,2005, 58(9):951-958.
33. 李莹,陈志红,周北凡,等.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用[J].中华心血管病杂志,2004,32(7)：643-647.
34. 周北凡.中国人群心血管病危险因素作用特点的前瞻性研究[J].中华流行病学杂志,2005,26(1)：58-61.
35. Liu J, Wang W, Wang M, Sun J, Li Y, Qi Y, Wu Z, Zhao D. Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level:A 15-year follow-up of the Chinese Multi-provincial Cohort Study [J]. Diabetes Res Clin Pract,2012, 96(2):217-224.
36. 王薇,赵冬,孙佳艺,等.中国11省市队列人群危险因素与不同类型心血管病发病危险的比较[J].中华心血管病杂志,2006,34(12)：1133-1137.
37. 江滨,方向华,刘运海,等.总胆固醇及甘油三酯与卒中亚型关系的前瞻性研究[J].中华心血管病杂志,2010,38(3)：268-271.
38. 徐忠,郑惠民,胡大萌,等.上海市市区15885名居民急性脑卒中危险因素的Cox回归分析[J].中华流行病学杂志,1994,15(2)：94-97.
39. 杜福昌,王海燕,姚才良,等.城乡队列人群脑卒中发病差异及其影响因素的前瞻性研究[J].中华流行病学杂志,1995,16(5)：278-280.
40. He Y, Lam TH, Li LS, He SF, Liang BQ. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China[J]. Ann Epidemiol,2004,14(1):1-7.
41. Sai XY, He Y, Men K, Wang B, Huang JY, Shi QL, Zhang L, Li LS, Choi BC, Yan YP. All-cause mortality and risk factors in a cohort of retired military male veterans, Xi'an, China:an 18-year follow up study[J]. BMC Public Health,2007,7:290.
42. 何耀,常青,黄久仪,等.军队男性中老年人脑卒中发病和死亡的队列研究[J].中华流行病学杂志,2003,24(6)：476-479.
43. 王桂清,黄久仪,郭吉平,等.上海市农村社区脑卒中队列人群基线调查报告[J].中华流行病学杂志,2006,27(1)：12-14.
44. 王艳,黄久仪,曹奕丰,等.上海市奉贤社区脑卒中危险因素队列研究基线调查和随访分析[J].中华流行病学杂志,2007,28(12)：1171-1174.
45. 张红叶,杨军,周北凡,等.我国十组人群脑卒中危险因素的前瞻性研究[J].中国慢性病预防与控制,1996,4：150-152.
46. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, Rao X, Zhou B, Detrano R, Liu K. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation,2006,114(21):2217-2225.
47. 李莹,陈志红,周北凡,等.我国中年人群血清TC/HDL—C比值与缺血性和出血性脑卒中发病危险性[J].中华神经科杂志,2005,38：305-308.
48. Collaboration APCS. Determinants of cardiovascular disease in the Asia Pacific region:protocol for a collaborative overview of cohort studies[J]. CVD Prevent,1999(2):281-289.
49. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group[J]. Lancet,1998, 352(9143):1801-1807.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke[J]. Lancet,2008, 371(9624):1612-1623.
3. 吴兆苏,姚崇华,赵冬,等.我国多省市心血管病趋势及决定因素的人群监测(中国MONICA方案)Ⅰ：发病率和死亡率监测结果[J].中华心血病杂志,1997,25(1)：6-11.
4. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES Ⅱ mortality study [J]. Am J Hypertens,2007,20(3):338-341.
5. Tunick PA, Kronzon I. Primary prevention of ischemic stroke[J]. Circulation, 2001,104(11):E59.
6. Michael KM, Shaughnessy M. Stroke prevention and management in older adults[J]. J Cardiovasc Nurs,2006,21(5 Suppl 1):S21-26.
7. Sacco RL. Newer risk factors for stroke[J]. Neurology,2001,57(5 Suppl 2):S31-34.
8. Wannamethee SG, Shaper AG, Ebrahim S. HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men[J]. Stroke,2000, 31(8):1882-1888.
9. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial[J]. N Engl J Med,1989,320(14):904-910.
10. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study [J]. BMJ,2006, 333(7557):22.
11. Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, Tsugane S. High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population:The JPHC study [J]. Atherosclerosis,2012,15(1):19-22.
12. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Sivenius J, Benetou V, Tuomilehto J, Koudstaal PJ et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE:a collaborative study among research centres in Europe[J]. J Epidemiol Community Health,2002,56 Suppl 1:ⅰ19-24.
13. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity [J]. JAMA,2000,284(3):311-318.
14. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group[J]. Arch Intern Med,1992,152(1):56-64.
15. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study[J]. JAMA,1995,274(2):131-136.
16. Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age[J]. Ann Intern Med,2001, 134(6):433-439.
17. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions:The Atherosclerosis Risk in Communities (ARIC) Study [J]. Circulation,2001,104(10):1108-1113.
18. Landau WM. Is cholesterol a risk factor for stroke?:No[J]. Arch Neurol,1999, 56(12):1521-1524.
19. Qizilbash N. Are risk factors for stroke and coronary disease the same?[J]. Curr Opin Lipidol,1998,9(4):325-328.
20. Demchuk AM, Hess DC, Brass LM, Yatsu FM. Is cholesterol a risk factor for stroke?:Yes[J]. Arch Neurol,1999,56(12):1518-1520.
21. Canoui-Poitrine F, Luc G, Bard JM, Ferrieres J, Yarnell J, Arveiler D, Morange P, Kee F, Evans A, Amouyel P, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke:the PRIME Study[J]. Cerebrovasc Dis,2010,30(3):252-259.
22. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke[J]. Stroke,2003,34(12):2930-2934.
23. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cholesterol and haemorrhagic stroke in men:Korea Medical Insurance Corporation Study [J]. Lancet,2001,357(9260):922-925.
24. Suzuki K, Izumi M, Sakamoto T, Hayashi M. Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan[J]. Cerebrovasc Dis,2011,31(1):100-106.
25. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region[J]. Int J Epidemiol,2003,32(4):563-572.
26. Cholesterol, diastolic blood pressure, and stroke:13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration[J]. Lancet, 1995,346(8991-8992):1647-1653.
27. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure:a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths[J]. Lancet,2007,370(9602):1829-1839.
28. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group[J]. Lancet,1998, 352(9143):1801-1807.
29.王薇,赵冬,刘静,等.中国35-64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2006,34(2)：169-173.
30. 江滨,方向华,刘运海,等.总胆固醇及甘油三酯与卒中亚型关系的前瞻性研究[J].中华心血管病杂志,2010,38(3)：268-271.
31. Zhang LF, Yang J, Hong Z, Yuan GQ Zhou BF, Zhao LC, Huang YN, Chen J, Wu YF. Proportion of different subtypes of stroke in China[J]. Stroke,2003, 34(9):2091-2096.
32. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes:initial findings from the North East Melbourne stroke incidence study (NEMESIS)[J]. Stroke,2001,32(8):1732-1738.
33. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamatelopoulos S. Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry[J]. Stroke,1999,30(2):363-370.
34. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of stroke in Germany--the Erlangen Stroke Project (ESPro):incidence and case fatality at 1,3, and 12 months[J]. Stroke, 1998,29(12):2501-2506.
35. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types:results from an international collaboration. International Stroke Incidence Collaboration[J]. Stroke,1997,28(3):491-499.
36. Woodward M, Barzi F, Martiniuk A, Fang X, Gu DF, Imai Y, Lam TH, Pan WH, Rodgers A, Suh I, et al. Cohort profile:the Asia Pacific Cohort Studies Collaboration[J]. Int J Epidemiol,2006,35(6):1412-1416.
37. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease):a major international collaboration. WHO MONICA Project Principal Investigators [J]. J Clin Epidemiol,1988, 41(2):105-114.
38. 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-419.
39. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults:findings from the National Health and Nutrition Examination Survey,1999 to 2000[J]. Circulation,2003,107(17):2185-2189.
40. 赵冬.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志,2003,24(3)：236-239.
41. Zhang Y, Tuomilehto J, Jousilahti P, Wang Y, Antikainen R, Hu G. Total and High-Density Lipoprotein Cholesterol and Stroke Risk[J]. Stroke,2012, PMID: 22496337
42. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project[J]. Stroke,2002,33(7):1863-1868.
43. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, JM G. Lipid levels and the risk of ischemic stroke in women[J]. Neurology,2007,68(8):556-562.
44. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, Rao X, Zhou B, Detrano R, Liu K. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation,2006,114(21):2217-2225.
45. 武阳丰,周北凡,李莹等.缺血性心血管疾病：一个反映血脂异常潜在危险的新指标[J].中华心血管病杂志,2004,32(2)：173-176.
46. 中国心血管病流行病学多中心研究专题协作组.90年代初期我国心血管病的总体形势与特点[J].中国慢性病预防与控制,1996,14(4)：145-149.
47. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y Sino-MONICA project:a collaborative study on trends and determinants in cardiovascular diseases in China, Part i:morbidity and mortality monitoring[J]. Circulation, 2001,103(3):462-468.
48. Ueshima H, Choudhury SR, Okayama A, Hayakawa T, Kita Y, Kadowaki T, Okamura T, Minowa M, Iimura O. Cigarette smoking as a risk factor for stroke death in Japan:NIPPON DATA80[J]. Stroke,2004,35(8):1836-1841.
49. Feigin V, Parag V, Lawes CM, Rodgers A, Suh I, Woodward M, Jamrozik K, Ueshima H. Smoking and elevated blood pressure are the most important risk factors for subarachnoid hemorrhage in the Asia-Pacific region:an overview of 26 cohorts involving 306,620 participants[J]. Stroke,2005,36(7):1360-1365.
50. Yamagishi K, Iso H, Kitamura A, Sankai T, Tanigawa T, Naito Y, Sato S, Imano H, Ohira T, Shimamoto T. Smoking raises the risk of total and ischemic strokes in hypertensive men[J]. Hypertens Res,2003,26(3):209-217.
51. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S. Blood pressure and cardiovascular disease in the Asia Pacific region[J]. J Hypertens,2003,21(4):707-716.
1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes[J]. J Biol Chem, 1995,270(45):26746-26749.
2. Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond[J]. Horm Metab Res,2002,34(9):469-474.
3. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity[J]. J Biol Chem,2003,278(11):9073-9085.
4. Lacquemant C, Froguel P, Lobbens S, Izzo P, Dina C, Ruiz J. The adiponectin gene SNP+45 is associated with coronary artery disease in Type 2 (non-insulin-dependent) diabetes mellitus[J]. Diabet Med,2004,21(7):776-781.
5. Qi L, Li T, Rimm E, Zhang C, Rifai N, Hunter D, Doria A, Hu FB. The+276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men[J]. Diabetes,2005,54(5):1607-1610.
6. Chiodini BD, Specchia C, Gori F, Barlera S, D'Orazio A, Pietri S, Crociati L, Nicolucci A, Franciosi M, Signorini S et al. Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes:an association study in an Italian population[J]. Ther Adv Cardiovasc Dis,2010, 4(4):223-230.
7. Leu HB, Chung CM, Lin SJ, Jong YS, Pan WH, Chen JW. Adiponectin gene polymorphism is selectively associated with the concomitant presence of metabolic syndrome and essential hypertension[J]. PLoS One,2011, 6(5):e19999.
8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia[J]. J Clin Endocrinol Metab,2001,86(5):1930-1935.
9. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men[J]. Metabolism, 2004,53(5):589-593.
10. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, et al. Hypoadiponectinemia is an independent risk factor for hypertension[J]. Hypertension,2004,43(6):1318-1323.
11. Bacci S, Menzaghi C, Ercolino T, Ma X, Rauseo A, Salvemini L, Vigna C, Fanelli R, Di Mario U, Doria A, et al. The+276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients[J]. Diabetes Care,2004,27(8):2015-2020.
12. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men[J]. JAMA,2004, 291(14):1730-1737.
13. Prior SL, Jones DA, Gill GV, Bain SC, Stephens JW. Association of the adiponectin rs266729 C>G variant and coronary heart disease in the low risk 'Golden Years' type 1 diabetes cohort[J]. Diabetes Res Clin Pract,2011, 91(3):e71-74.
14. Oguri M, Kato K, Yokoi K, Itoh T, Yoshida T, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, et al. Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome[J]. Atherosclerosis, 2009,206(2):486-493.
15. Hegener HH, Lee IM, Cook NR, Ridker PM, Zee RY Association of adiponectin gene variations with risk of incident myocardial infarction and ischemic stroke:a nested case-control study[J]. Clin Chem,2006, 52(11):2021-2027.
16. Leu HB, Chung CM, Chuang SY, Bai CH, Chen JR, Chen JW, Pan WH. Genetic variants of connexin37 are associated with carotid intima-medial thickness and future onset of ischemic stroke[J]. Atherosclerosis,2011, 214(1):101-106.
17. Liu F, He Z, Deng S, Zhang H, Li N, Xu J. Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population[J]. Mol Biol Rep,2011,38(3):1983-1988.
18. Ong KL, Li M, Tso AW, Xu A, Cherny SS, Sham PC, Tse HF, Lam TH, Cheung BM, Lam KS. Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese[J]. Eur J Endocrinol,2010,163(2):251-257.
19. Yamada Y, Kato K, Oguri M, Yoshida T, Yokoi K, Watanabe S, Metoki N, Yoshida H, Satoh K, Ichihara S, et al. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome[J]. Int J Mol Med,2008,21(6):801-808.
20. Yan WL, Chen SF, Huang JF, Shen Y, Qiang BQ, Liu DH, Gu DF. Common SNPs of APM1 gene are not associated with hypertension or obesity in Chinese population[J]. Biomed Environ Sci,2006,19(3):179-184.
21. 陈小良,程锦泉,张仁利,刘建平,李晓霞,童叶青,耿艺介.脂联素基因多态性与北方汉族人群缺血陛脑卒中易感性关系研究[J].中华流行病学杂志,2010,31(2)：129-132.
22. 贾玫,乔博明,张正,冯秀玲,秦效英,孙媛媛.脂联素启动子基因多态性和脂联素水平与高血压及并发症的相关性研究[J].中国实验诊断学,2008,12(2)：222-226.
23. 李晓霞,关红军,郭毓鹏,陈小良,杨印东,周君,程锦泉,聂绍发.脂联素基因多态性与缺血性脑卒中关系[J].中国公共卫生,2009,25(11)：1341-1343.
24. 唐晓明,李洁琪,吴立荣,庄梅,吕贞.脂联素基因+45T/G多态性与原发性高血压相关性的研究[J].天津医药,2008,36(10)：762-764.
25. 王忠莉,夏冰,姜黎,胡正国,曹萍.脂联素基因多态性与原发性高血压的关系[J].医学新知杂志,2008,18(1)：25-29.
26. 张子波,于丽军,杨康鹃,徐良慰,盛天昕,郝萍,王玉萍,孟繁平.延边朝鲜族和汉族脂联素启动子SNPs与原发性高血压的相关性[J].遗传,2011,33(1)：54-59.
27. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, et al. Disruption of adiponectin causes insulin resistance and neointimal formation[J]. J Biol Chem,2002, 277(29):25863-25866.
28. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, et al. Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin[J]. Circulation,1999,100(25):2473-2476.
29. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages[J]. Blood, 2000,96(5):1723-1732.
30. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway[J]. Circulation,2000,102(11):1296-1301.
31. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages[J]. Circulation, 2001,103(8):1057-1063.
32. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell[J]. Circulation,2002,105(24):2893-2898.
33. Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers[J]. Eur Heart J,2005,26(16):1640-1646.
34. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Sakamoto T, Yoshimura M, Kimura K, Umemura S, Ogawa H. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men[J]. Circ J,2007,71(11):1703-1709.
35. Koz C, Uzun M, Yokusoglu M, Baysan O, Erinc K, Sag C, Hasimi A, Isik E. Evaluation of plasma adiponectin levels in young men with coronary artery disease[J]. Acta Cardiol,2007,62(3):239-243.
36. Lu G, Chiem A, Anuurad E, Havel PJ, Pearson TA, Ormsby B, Berglund L. Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity[J]. Transl Res,2007,149(6): 317-323.
37. Zhang BC, Liu WJ, Che WL, Xu YW. Serum Total Adiponectin Level and Risk of Cardiovascular Disease in Han Chinese Populations:A Meta-Analysis of 17 Case-Control Studies[J]. Clin Endocrinol (Oxf),2011, doi:10.1111/j. 1365-2265.2011.04260.ⅹ.
38. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women[J]. Atherosclerosis,2011,219(1):322-329.
39. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women[J]. J Clin Endocrinol Metab, 2005,90(10):5677-5683.
40. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women[J]. J Clin Endocrinol Metab, 2008,93(9):3357-3364.
41. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA,2000,283(15): 2008-2012.
42. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, et al. Replicating genotype-phenotype associations[J]. Nature,2007,447(7145):655-660.
43. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses.Available from:URL:http://www.ohri.ca/programs/ clinical_epidemiology/oxford.htm [cited 2011 Sep 19].
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses[J]. BMJ,2003,327(7414):557-560.
45. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ,1997,315(7109):629-634.
46. DerSimonian R, Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials, 1986,7(3):177-188.
47. Ioannidis JP, Trikalinos TA. Early extreme contradictory estimates may appear in published research:the Proteus phenomenon in molecular genetics research and randomized trials[J]. J Clin Epidemiol,2005,58(6):543-549.
48. Qi L, Doria A, Manson JE, Meigs JB, Hunter D, Mantzoros CS, Hu FB. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes[J]. Diabetes,2006,55(5):1512-1516.
49. Sun K, Li Y, Wei C, Tong Y, Zheng H, Guo Y. Recessive protective effect of ADIPOQ rs1501299 on cardiovascular diseases with type 2 diabetes:A meta-analysis[J]. Mol Cell Endocrinol,2012,349(2):162-169.
50. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women[J]. Atherosclerosis,2011,219(1):322-329.
51. Siitonen N, Pulkkinen L, Lindstrom J, Kolehmainen M, Eriksson JG, Venojarvi M, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations:the Finnish Diabetes Prevention Study [J]. BMC Med Genet,2011,12:5.
52. Hivert MF, Manning AK, McAteer JB, Florez JC, Dupuis J, Fox CS, O'Donnell CJ, Cupples LA, Meigs JB. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits:the Framingham Offspring Study [J]. Diabetes,2008,57(12):3353-3359.
53. Kyriakou T, Collins LJ, Spencer-Jones NJ, Malcolm C, Wang X, Snieder H, Swaminathan R, Burling KA, Hart DJ, Spector TD, et al. Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity [J]. J Hum Genet,2008, 53(8):718-727.
54. Richards JB, Waterworth D, O'Rahilly S, Hivert MF, Loos RJ, Perry JR, Tanaka T, Timpson NJ, Semple RK, Soranzo N, et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels[J]. PLoS Genet,2009,5(12):e1000768.
55. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease[J]. Diabetes, 2007,56(5):1198-1209.
56. Gong M, Long J, Liu Q, Deng HC. Association of the ADIPOQ rs 17360539 and rs266729 polymorphisms with type 2 diabetes:a meta-analysis[J]. Mol Cell Endocrinol,2010,325(1-2):78-83.
57. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls[J]. Br J Clin Pharmacol,2001,52(5): 489-499.
58. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome[J]. J Clin Invest,2006,116(7):1784-1792.
59. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HE Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30)[J]. J Biol Chem,2002, 277(33):29359-29362.
60. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, Kawamoto T, Matsumoto S, Nagaretani H, Kumada M, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease[J]. J Am Coll Cardiol,2004,43(7):1195-1200.
61. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, et al. Adiponectin in renal disease:relationship to phenotype and genetic variation in the gene encoding adiponectin[J]. Kidney Int,2004,65(1):274-281.
62. Filippi E, Sentinelli F, Romeo S, Area M, Berni A, Tiberti C, Verrienti A, Fanelli M, Fallarino M, Sorropago G, et al. The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age
64. Gable DR, Matin J, Whittall R, Cakmak H, Li KW, Cooper J, Miller GJ, Humphries SE. Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects[J]. Ann Hum Genet,2007,71(Pt 4):453-466.
65. Wang JN LS. Adiponectin gene polymorphism in han people of Jilin region and its association with coronary heart disease[J]. Chinese Journal of Laboratory Diagnosis,2006,10(11):1272-1274.
66. Jung CH, Rhee EJ, Kim SY, Shin HS, Kim BJ, Sung KC, Kim BS, Lee WY, Kang JH, Oh KW, et al. Associations between two single nucleotide polymorphisms of adiponectin gene and coronary artery diseases[J]. Endocr J, 2006,53(5):671-677.
67. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D, Rimm EB. Single nucleotide polymorphisms at the adiponectin locus and risk of coronary heart disease in men and women[J]. Obesity (Silver Spring),2007, 15(8):2051-2060.
68. Lu f WL, Yang ZJ, Zhu TB, Wang ZG, Zhu HJ, Tang NP, Cao KJ, Huang J, Gui M. Correlation between single nucleotide polymorphism(SNP+276 G/T) of adiponectin gene and coronary artery disease in non-diabetic population.[J]. Acta universitatis medicinalis nanjing,2007,27(7):736-739.
69. Liang XZ XJ, Wang J, Yu P, Qi WG, Ma L, Hu B, Luo Y, Zhang DF. Correlation between single nucleotide polymorphism (SNP+276G/T) of adiponectin gene and coronary artery disease[J]. Chinese Journal of Cardiovascular Review,2008,6(11):838-840.
70. Chang YC, Jiang JY, Jiang YD, Chiang FT, Hwang JJ, Lien WP, Chuang LM. Interaction of ADIPOQ genetic polymorphism with blood pressure and plasma cholesterol level on the risk of coronary artery disease[J]. Circ J,2009, 73(10):1934-1938.
71. Foucan L, Ezourhi N, Maimaitiming S, Hedreville S, Inamo J, Atallah A, Bangou-Bredent J, Aubert R, Chout R, Fumeron F, et al. Adiponectin multimers and ADIPOQ T45G in coronary artery disease in Caribbean type 2 diabetic subjects of African descent[J]. Obesity (Silver Spring),2010, 18(7):1466-1468.
72. Zhang XL PW, Lu L, Wu LiQ, Gu G, Wand LJ, Yan XX, Chen QJ, Shen WF. Correlation of adiponectin gene polymorphisms with coronary artery disease and plaque progression.[J]. Journal of shanghai jiaotong university (medical science),2009,29(4):435-439.
73. Zhong C, Zhen D, Qi Q, Genshan M. A lack of association between adiponectin polymorphisms and coronary artery disease in a Chinese population[J]. Genet Mol Biol,2010,33(3):428-433.
74. De Caterina R, Talmud PJ, Merlini PA, Foco L, Pastorino R, Altshuler D, Mauri F, Peyvandi F, Lina D, Kathiresan S, et al. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction [J]. Atherosclerosis,2011,214(2):397-403.
75. Xu L LW. Correlation of adiponectin gene SNP+45 T/G polymorphism with coronary heart disease[J]. Chinese Journal of Pathophysiology,2010, 26(6):1064-1068.
76. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Hussain T. Adiponectin gene variants and the risk of coronary artery disease in patients with type 2 diabetes[J]. Mol Biol Rep,2011,38(6):3703-3708.
77. Rodriguez-Rodriguez L, Garcia-Bermudez M, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA. Lack of association between ADIPOQ rs266729 and ADIPOQ rs 1501299 polymorphisms and cardiovascular disease in rheumatoid arthritis patients[J]. Tissue Antigens,2011,77(1):74-78.
78. Chen XL CH, Zhang RL, Liu JP, Li XX, Tong YQ, Geng YJ. Study on the relationship between polymorphism of adiponectin gene and risk of ischemic stroke among Han population in the Northern parts of China[J]. Chin J Epidemiol,2010,31(2):129-132.
79. Sabouri S, Ghayour-Mobarhan M, Moohebati M, Hassani M, Kassaeian J, Tatari F, Mahmoodi-kordi F, Esmaeili HA, Tavallaie S, Paydar R, et al. Association between 45T/G polymorphism of adiponectin gene and coronary artery disease in an Iranian population[J]. ScientificWorldJournal,2011, 11:93-101.
80. Esteghamati A, Mansournia N, Nakhjavani M, Mansournia MA, Nikzamir A, Abbasi M. Association of +45(T/G) and +276(G/T) polymorphisms in the adiponectin gene with coronary artery disease in a population of Iranian patients with type 2 diabetes[J]. Mol Biol Rep,2012,39(4):3791-3797.
81. Boumaiza I, Omezzine A, Rejeb J, Rebhi L, Ben Rejeb N, Nabli N, Ben Abdelaziz A, Boughzala E, Bouslama A. Single-nucleotide polymorphisms at the adiponectin locus and risk of coronary artery disease in Tunisian coronaries[J]. J Cardiovasc Med (Hagerstown),2011,12(9):619-624.
82. Katakami N, Kaneto H, Matsuoka TA, Takahara M, Maeda N, Shimizu I, Ohno K, Osonoi T, Kawai K, Ishibashi F, et al. Adiponectin G276T gene polymorphism is associated with cardiovascular disease in Japanese patients with type 2 diabetes[J]. Atherosclerosis,220(2):437-442.
83. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, Yeh J, Best LG. Adiponectin and coronary heart disease:the Strong Heart Study [J]. Arteriosclerosis, thrombosis, and vascular biology,2005,25(3):e15-16.
84. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes[J]. Diabetes, 2005,54(2):534-539.
85. Kanaya AM, Wassel Fyr C, Vittinghoff E, Havel PJ, Cesari M, Nicklas B, Harris T, Newman AB, Satterfield S, Cummings SR. Serum adiponectin and coronary heart disease risk in older Black and White Americans[J]. J Clin Endocrinol Metab,2006,91(12):5044-5050.
86. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH. Adiponectin and coronary heart disease:a prospective study and meta-analysis[J]. Circulation,2006,114(7):623-629.
87. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men:results from the 18-year follow-up of a large cohort from southern Germany [J]. J Am Coll Cardiol, 2006,48(7):1369-1377.
88. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality:the Rancho Bernardo study[J]. Am J Epidemiol,2007,165(2):164-174.
89. Hatano Y, Matsumoto M, Ishikawa S, Kajii E. Plasma adiponectin level and myocardial infarction:the JMS Cohort Study[J]. J Epidemiol,2009, 19(2):49-55.
90. Cote M, Cartier A, Reuwer AQ, Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Kastelein JJ, Boekholdt SM, Khaw KT. Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study)[J]. Am J Cardiol,2011, 108(3):367-373.
91. Kanaya AM, Fyr CW, Vittinghoff E, Havel PJ, Cesari M, Nicklas B, Harris T, Newman AB, Satterfield S, Cummings SR. Serum adiponectin and coronary heart disease risk in Older Black and White Americans[J]. Journal of Clinical Endocrinology and Metabolism,2006,91(12):5044-5050.
1. World Health Organization. World Health Report 2003. Shaping the future. World Health Organization:Geneva.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke[J]. Lancet,2008, 371(9624):1612-1623.
3. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y. Sino-MONICA project:a collaborative study on trends and determinants in cardiovascular diseases in China, Part ⅰ:morbidity and mortality monitoring [J]. Circulation, 2001,103(3):462-468.
4. 赵冬.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志,2003,24(3)：236-239.
5. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, et al. Major causes of death among men and women in China[J]. N Engl J Med,2005,353(11):1124-1134.
6. 吴兆苏,姚崇华,赵冬,等.我国多省市心血管病趋势及决定因素的人群监测(中国MONICA方案)Ⅰ：发病率和死亡率监测结果[J].中华心血病杂志,1997,25(1)：6-11.
7. Carallo C, Lucca LF, Ciamei M, Tucci S, de Franceschi MS. Wall shear stress is lower in the carotid artery responsible for a unilateral ischemic stroke[J]. Atherosclerosis,2006,185(1):108-113.
8. Birchall D, Zaman A, Hacker J, Davies G, Mendelow D. Analysis of haemodynamic disturbance in the atherosclerotic carotid artery using computational fluid dynamics[J]. Eur Radiol,2006,16(5):1074-1083.
9. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study[J]. Am J Hypertens,2007, 20(3):338-341.
10. Michael KM, Shaughnessy M. Stroke prevention and management in older adults[J]. J Cardiovasc Nurs,2006,21(5 Suppl 1):S21-26.
11. Mozaffarian D, Fried LP, Burke GL, Fitzpatrick A, Siscovick DS. Lifestyles of older adults:can we influence cardiovascular risk in older adults?[J]. Am J Geriatr Cardiol,2004,13(3):153-160.
12. Nilsson PM. Reducing the risk of stroke in elderly patients with hypertension: a critical review of the efficacy of antihypertensive drugs [J]. Drugs Aging, 2005,22(6):517-524.
13. Redon J, Cea-Calvo L, Lozano JV, Marti-Canales JC, Llisterri JL, Aznar J, Gonzalez-Esteban J. Differences in blood pressure control and stroke mortality across Spain:the Prevencion de Riesgo de Ictus (PREV-ICTUS) study [J]. Hypertension,2007,49(4):799-805.
14. Tunick PA, Kronzon I. Primary prevention of ischemic stroke[J]. Circulation, 2001,104(11):E59.
15. Sacco RL. Newer risk factors for stroke[J]. Neurology,2001,57(5 Suppl 2):S31-34.
16. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity[J]. JAMA,2000,284(3):311-318.
17. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group[J]. Arch Intern Med,1992,152(1):56-64.
18. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study[J]. JAMA,1995, 274(2):131-136.
19. Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age[J]. Ann Intern Med,2001, 134(6):433-439.
20. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions:The Atherosclerosis Risk in Communities (ARIC) Study[J]. Circulation,2001,104(10):1108-1113.
21. Collaboration APCS. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region[J]. Diabetologia,2007,50(11):2289-2297.
22. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study [J]. BMJ,2006, 333(7557):22.
23. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure:a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths[J]. Lancet,2007, 370(9602):1829-1839.
24. Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, Tsugane S. High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population:The JPHC study[J]. Atherosclerosis,2012,15(1):19-22.
25. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region[J]. Int J Epidemiol,2003,32(4):563-572.
26. 王薇,赵冬,刘静,等.中国35-64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2006,34(2)：169-173.
27. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, Huang YN, Chen J, Wu YF. Proportion of different subtypes of stroke in China[J], Stroke,2003, 34(9):2091-2096.
28. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes:initial findings from the North East Melbourne stroke incidence study (NEMESIS)[J]. Stroke,2001,32(8):1732-1738.
29. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamatelopoulos S. Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry[J]. Stroke,1999,30(2):363-370.
30. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of stroke in Germany--the Erlangen Stroke Project (ESPro):incidence and case fatality at 1,3, and 12 months[J]. Stroke,1998,29(12):2501-2506.
31. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types:results from an international collaboration. International Stroke Incidence Collaboration[J]. Stroke,1997,28(3):491-499.
32. Zhang XF, Attia J, D'Este C, Yu XH, Wu XG. A risk score predicted coronary heart disease and stroke in a Chinese cohort[J]. J Clin Epidemiol,2005, 58(9):951-958.
33. 李莹,陈志红,周北凡,等.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用[J].中华心血管病杂志,2004,32(7)：643-647.
34. 周北凡.中国人群心血管病危险因素作用特点的前瞻性研究[J].中华流行病学杂志,2005,26(1)：58-61.
35. Liu J, Wang W, Wang M, Sun J, Li Y, Qi Y, Wu Z, Zhao D. Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level:A 15-year follow-up of the Chinese Multi-provincial Cohort Study [J]. Diabetes Res Clin Pract,2012, 96(2):217-224.
36. 王薇,赵冬,孙佳艺,等.中国11省市队列人群危险因素与不同类型心血管病发病危险的比较[J].中华心血管病杂志,2006,34(12)：1133-1137.
37. 江滨,方向华,刘运海,等.总胆固醇及甘油三酯与卒中亚型关系的前瞻性研究[J].中华心血管病杂志,2010,38(3)：268-271.
38. 徐忠,郑惠民,胡大萌,等.上海市市区15885名居民急性脑卒中危险因素的Cox回归分析[J].中华流行病学杂志,1994,15(2)：94-97.
39. 杜福昌,王海燕,姚才良,等.城乡队列人群脑卒中发病差异及其影响因素的前瞻性研究[J].中华流行病学杂志,1995,16(5)：278-280.
40. He Y, Lam TH, Li LS, He SF, Liang BQ. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China[J]. Ann Epidemiol,2004,14(1):1-7.
41. Sai XY, He Y, Men K, Wang B, Huang JY, Shi QL, Zhang L, Li LS, Choi BC, Yan YP. All-cause mortality and risk factors in a cohort of retired military male veterans, Xi'an, China:an 18-year follow up study[J]. BMC Public Health,2007,7:290.
42. 何耀,常青,黄久仪,等.军队男性中老年人脑卒中发病和死亡的队列研究[J].中华流行病学杂志,2003,24(6)：476-479.
43. 王桂清,黄久仪,郭吉平,等.上海市农村社区脑卒中队列人群基线调查报告[J].中华流行病学杂志,2006,27(1)：12-14.
44. 王艳,黄久仪,曹奕丰,等.上海市奉贤社区脑卒中危险因素队列研究基线调查和随访分析[J].中华流行病学杂志,2007,28(12)：1171-1174.
45. 张红叶,杨军,周北凡,等.我国十组人群脑卒中危险因素的前瞻性研究[J].中国慢性病预防与控制,1996,4：150-152.
46. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, Rao X, Zhou B, Detrano R, Liu K. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation,2006,114(21):2217-2225.
47. 李莹,陈志红,周北凡,等.我国中年人群血清TC/HDL—C比值与缺血性和出血性脑卒中发病危险性[J].中华神经科杂志,2005,38：305-308.
48. Collaboration APCS. Determinants of cardiovascular disease in the Asia Pacific region:protocol for a collaborative overview of cohort studies[J]. CVD Prevent,1999(2):281-289.
49. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group[J]. Lancet,1998, 352(9143):1801-1807.